| 000 | 01666 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250517134918.0 | ||
| 264 | 0 | _c20180322 | |
| 008 | 201803s 0 0 eng d | ||
| 022 | _a1365-2893 | ||
| 024 | 7 |
_a10.1111/jvh.12684 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJanjua, N Z | |
| 245 | 0 | 0 |
_aShift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study. _h[electronic resource] |
| 260 |
_bJournal of viral hepatitis _c08 2017 |
||
| 300 |
_a624-630 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 | _aBritish Columbia |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHealthcare Disparities |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferons _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOligopeptides _xtherapeutic use |
| 650 | 0 | 4 |
_aProline _xanalogs & derivatives |
| 650 | 0 | 4 |
_aRibavirin _xtherapeutic use |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aIslam, N | |
| 700 | 1 | _aWong, J | |
| 700 | 1 | _aYoshida, E M | |
| 700 | 1 | _aRamji, A | |
| 700 | 1 | _aSamji, H | |
| 700 | 1 | _aButt, Z A | |
| 700 | 1 | _aChong, M | |
| 700 | 1 | _aCook, D | |
| 700 | 1 | _aAlvarez, M | |
| 700 | 1 | _aDarvishian, M | |
| 700 | 1 | _aTyndall, M | |
| 700 | 1 | _aKrajden, M | |
| 773 | 0 |
_tJournal of viral hepatitis _gvol. 24 _gno. 8 _gp. 624-630 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/jvh.12684 _zAvailable from publisher's website |
| 999 |
_c26826167 _d26826167 |
||